Invivyd Inc. (Nasdaq: IVVD) has announced the successful closing of its underwritten public offering, raising approximately $57.5 million. The offering included 89,234,480 shares of common stock, with an additional option exercised by the underwriter for 14,423,076 shares, priced at $0.52 per share. Additionally, pre-funded warrants for 21,342,442 shares were offered at $0.5199 per warrant. Cantor Fitzgerald & Co. served as the sole book-running manager for the offering, which was led by RA Capital Management and Janus Henderson Investors, and saw participation from various healthcare-focused investors. Invivyd plans to allocate the net proceeds towards the development of the VYD2311 clinical program, research on respiratory syncytial virus (RSV) and measles, and efforts related to the Spike Protein Elimination and Recovery (SPEAR) Study Group, as well as for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.